---
title: "Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide"
description: "How formal meetings with FDA, EMA, and China's CDE compare: meeting types, when to request them, scheduling timelines, and fees."
---

[News, Events & Resources | Crystal Bio Solutions](https://www.crystalbiosolutions.com/news-and-events)

# [Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide](https://www.crystalbiosolutions.com/news-and-events/regulatory-meetings-with-fda-ema-and-chinas-cde-a-side-by-side-guide)

 Written by [CBS Marketing Team](https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team) | Nov 22, 2026, 5:58:48 PM

To help sponsors develop drugs in a scientifically sound, risk-controlled way, regulators in the US, the EU, and China offer several formal channels for sponsors to get timely advice. Knowing which meeting fits which stage, and how long each takes to schedule, helps keep a global program on track. This guide compares the three systems.

## United States: FDA formal meetings

FDA offers a series of formal meetings during development, described in its formal meetings guidance for PDUFA products (finalized in August 2026). Formats include face-to-face meetings, video conferences, teleconferences, and written responses only. For each meeting type, FDA commits to responding to the meeting request within a set time and to holding the meeting (or sending written responses) within a set time of receiving the request.

### Type A

For stalled programs or important safety issues. Examples: dispute resolution meetings (21 CFR 10.75, 312.48, and 314.103); meetings on a clinical hold to discuss a new path forward; special protocol assessment meetings requested after FDA's evaluation; post-action meetings requested within 3 months of an FDA regulatory action other than approval; and meetings requested within 30 days of a refuse-to-file letter.

**Timeline:** FDA responds to the request within 14 days and holds the meeting within 30 days of the request.

### Type B

Tied to major development milestones. Examples: pre-IND, pre-NDA/BLA, and pre-EUA meetings; meetings to review the Integrated Summary of Efficacy (ISE) and Integrated Summary of Safety (ISS); post-action meetings requested more than 3 months after a regulatory action other than approval; meetings on REMS or postmarketing requirements outside a marketing application review; and meetings on the overall development plan for a Breakthrough Therapy.

**Timeline:** FDA responds to the request within 21 days and holds the meeting within 60 days of the request.

### Type B (EOP)

Held when a development phase is complete and the program is ready for the next. Includes End-of-Phase 1 meetings for products treating life-threatening or severely debilitating diseases and for drugs under accelerated approval, and End-of-Phase 2/pre-Phase 3 meetings.

**Timeline:** FDA responds to the request within 14 days and holds the meeting within 70 days of the request.

### Type C

Any meeting on product development or review not covered by Type A, B, D, or INTERACT. Examples: End-of-Phase 2A meetings, OTC monograph feedback, and Phase 4 meetings.

**Timeline:** FDA responds to the request within 21 days and holds the meeting within 75 days of the request.

### Type D

A focused meeting on a narrow set of issues: generally no more than two focus topics, with sponsor attendees from no more than three disciplines or divisions. Examples: follow-up questions on new issues raised in a formal meeting, narrow questions needing regulatory input, and questions on innovative development approaches.

**Timeline:** FDA responds to the request within 14 days and holds the meeting within 50 days of the request.

### INTERACT

Initial Targeted Engagement for Regulatory Advice on CDER and CBER ProducTs (INTERACT) meetings give sponsors of novel products early, non-binding advice on CMC, pharmacology/toxicology, or clinical plans before a pre-IND meeting. They help FDA understand unique challenges such as unknown safety profiles, complex manufacturing, novel devices, or cutting-edge assays.

**Timeline:** FDA responds to the request within 21 days and holds the meeting within 75 days of the request.

**Fees:** FDA charges no fee for these meetings.

FDA also runs program-specific meetings, including GDUFA scientific meetings for generic drugs (before, during, and after ANDA review), BsUFA meetings for biosimilars, MDUFA meetings for devices (including Q-Submissions), and advisory committee meetings, such as ODAC, for new targets, new molecular entities, or programs with incomplete clinical data.

## China: CDE communication meetings

CDE communication meetings are held between the applicant and CDE's review team, during development or technical review, on key technical questions not covered by current guidelines. Formats are face-to-face meetings, video conferences, teleconferences, or written responses.

### Type I

To resolve major safety issues during clinical trials, or major technical issues in developing breakthrough therapies.

**Timeline:** usually scheduled within 30 working days of the application.

### Type II

Held at key development milestones: pre-IND; End-of-Phase 1, End-of-Phase 2 (or before Phase 2), and pre-Phase 3 meetings; pre-NDA/BLA; risk assessment and control meetings; and meetings on conditional approval or priority review.

**Timeline:** usually scheduled within 60 working days.

### Type III

All other meetings. Examples: new indications or new combinations; important questions on urgently needed or rare disease drugs; major development issues for complex generics, consistency evaluation, or re-evaluation; design of complex nonclinical studies; technical disagreements with CDE; drugs in cutting-edge fields; postapproval changes; safety assessment and risk management issues during trials; and postmarketing trial design.

**Timeline:** usually scheduled within 75 working days.

**Fees:** CDE charges no fee for these meetings.

## European Union: EMA scientific advice

EU interactions include scientific advice (SA), protocol assistance (PA) for orphan medicines, and pre-MAA meetings. The Committee for Medicinal Products for Human Use (CHMP) provides SA and PA based on recommendations from the Scientific Advice Working Party (SAWP). Sponsors can request SA or PA at any stage, from early development to after approval, but most request it after Phase 1 or once Phase 2 data are available. If EMA raises no major objections, the path to authorization can move faster; major objections can affect approval.

- **Purpose:** scientific advice on specific development questions.
- **Scope:** CMC, pharmacology and toxicology, clinical, statistics, overall development strategy, orphan designation, and pediatric investigation plans.
- **Timeline:** SAWP meets monthly, and EMA publishes the year's meeting dates in advance. Requests must be submitted to match that calendar.
- **Fees:** EMA charges for scientific advice under the fee regulation that applies from January 1, 2025 (Regulation (EU) 2024/568). The fee depends on the scope of the request and must be paid before the advice is given. Significant reductions apply: 90% for SMEs (100% for SMEs with designated orphan medicines), 75% for protocol assistance requested by non-SME sponsors of orphan medicines, 65% for advanced therapy medicinal products, and 100% for advice limited to pediatric development. Check EMA's current fee tables for the exact amount.

## How the three systems compare

The US and Chinese systems are broadly similar in meeting types and in charging no fees. The main differences are FDA's INTERACT meetings and the scheduling timelines (FDA counts calendar days; CDE counts working days). The EU system has fewer categories, but its scope covers most of what US and Chinese meetings address, and it charges fees based on the scope of the advice.

Planning a global program? Our [regulatory affairs team](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt) can help you decide which meetings to request and when. [Contact us](https://www.crystalbiosolutions.com/contact-us) to discuss your program.

## Sources

- FDA. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products: Guidance for Industry. Final, August 2026.
- EMA. [Fees payable to the European Medicines Agency](https://www.ema.europa.eu/en/about-us/fees-payable-european-medicines-agency).

[View full post](https://www.crystalbiosolutions.com/news-and-events/regulatory-meetings-with-fda-ema-and-chinas-cde-a-side-by-side-guide)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team"
  },
  "dateModified" : "2026-11-22T18:22:11.934Z",
  "datePublished" : "2026-11-22T17:58:48Z",
  "headline" : "Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1024,
    "url" : "https://www.crystalbiosolutions.com/hubfs/website-assets/experts-collaborating-at-crystal-bio-solutions.png",
    "width" : 1536
  },
  "mainEntityOfPage" : "https://www.crystalbiosolutions.com/news-and-events/regulatory-meetings-with-fda-ema-and-chinas-cde-a-side-by-side-guide",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://146565877.fs1.hubspotusercontent-eu1.net/hubfs/146565877/CBS%20VI%20v1/Crystal%20Bio%20Solution-%E7%99%BD%E5%BA%95%E5%9B%BE%E7%89%87.jpg",
      "width" : 196.30608
    },
    "name" : "News, Events & Resources"
  }
}
```